应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AGMB AgomAb Therapeutics
盘后交易 03-17 17:37:01 EDT
13.71
-0.60
-4.23%
盘后
13.60
-0.11
-0.80%
16:50 EDT
最高
14.59
最低
13.20
成交量
14.70万
今开
14.29
昨收
14.32
日振幅
9.71%
总市值
6.68亿
流通市值
1.71亿
总股本
4,874万
成交额
204.44万
换手率
1.18%
流通股本
1,250万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Leerink Partners首次覆盖AgomAb Therapeutics,给予“跑赢大盘”评级,目标价36美元
美股速递 · 03-03
Leerink Partners首次覆盖AgomAb Therapeutics,给予“跑赢大盘”评级,目标价36美元
异动解读 | 新股上市遇冷,AgomAb Therapeutics盘中大跌18.72%
异动解读 · 02-07
异动解读 | 新股上市遇冷,AgomAb Therapeutics盘中大跌18.72%
比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元
智通财经 · 01-30
比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元
加载更多
公司概况
公司名称:
AgomAb Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
AgomAb Therapeutics NV最初于2017年4月13日根据比利时法律注册成立,是一家比利时私人有限责任公司。该公司是一家临床阶段的生物制药实体,致力于开发针对免疫学和炎症性疾病的创新疾病改善疗法,特别专注于存在重大未满足医疗需求的慢性纤维化疾病。其候选产品旨在针对既定途径,并使用经过验证的模式来增强疗效,同时最大限度地减少全身毒性,从而解决先前治疗的局限性。其使命是创造不仅能解决纤维化,还能恢复器官功能的疗法,让患者过上更充实、更健康的生活。
发行价格:
--
{"stockData":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":13.71,"timestamp":1773777600000,"preClose":14.315,"halted":0,"volume":147046,"hourTrading":{"tag":"盘后","latestPrice":13.6,"preClose":13.71,"latestTime":"16:50 EDT","volume":2292,"amount":31506.732755999998,"timestamp":1773780655342,"change":-0.11,"changeRate":-0.008023,"amplitude":0.05981},"delay":0,"changeRate":-0.04226336011177078,"floatShares":12500000,"shares":48736779,"eps":-3391.5288,"marketStatus":"盘后交易","change":-0.605,"latestTime":"03-17 17:37:01 EDT","open":14.29,"high":14.59,"low":13.2,"amount":2044395.389646,"amplitude":0.097101,"askPrice":13.89,"askSize":20,"bidPrice":13.19,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3391.5288,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773792000000},"marketStatusCode":4,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":14.315,"postHourTrading":{"tag":"盘后","latestPrice":13.6,"preClose":13.71,"latestTime":"16:50 EDT","volume":2292,"amount":31506.732755999998,"timestamp":1773780655342,"change":-0.11,"changeRate":-0.008023,"amplitude":0.05981},"volumeRatio":2.219475},"requestUrl":"/m/hq/s/AGMB","defaultTab":"news","newsList":[{"id":"1119430627","title":"Leerink Partners首次覆盖AgomAb Therapeutics,给予“跑赢大盘”评级,目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119430627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119430627?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:56","pubTimestamp":1772538974,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布启动对生物技术公司AgomAb Therapeutics(AGMB)的研究覆盖,并给予“跑赢大盘”评级。该机构为该公司设定了36美元的目标股价,显示出对其未来增长潜力的积极预期。\n此次覆盖标志着市场对AgomAb Therapeutics研发管线的关注升温。Leerink Partners的看好评级基于对公司核心技术与业务前景的深入评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"gpt_icon":0},{"id":"1129897501","title":"异动解读 | 新股上市遇冷,AgomAb Therapeutics盘中大跌18.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129897501","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129897501?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:54","pubTimestamp":1770400445,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics(AGMB)今日盘中股价大跌18.72%,引起了市场的广泛关注。消息面上,该公司于周五正式登陆美股市场,但新股表现不佳,开盘即大幅下跌。根据相关报道,其IPO价格为16美元,上市后股价持续走低,市场对其首秀反应冷淡。AgomAb Therapeutics是一家总部位于比利时的临床阶段生物制药公司,专注于开发针对免疫与炎症疾病的创新疗法。公司估值约为7.164亿美元,其核心候选药物针对纤维狭窄型克罗恩病等慢性纤维化适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AGMB"],"gpt_icon":0},{"id":"2607091502","title":"比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091502","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607091502?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:16","pubTimestamp":1769757418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,比利时二期生物科技公司AgomAb Therapeutics于美东时间周四公布了其美股IPO条款。该公司专注于开发针对克罗恩病及其他纤维化疾病的TGFβ抑制剂。按拟议发行价区间中值计算,AgomAb Therapeutics的完全稀释后市值将达到8.75亿美元。AgomAb Therapeutics是一家临床阶段生物制药公司,致力于开发针对免疫与炎症疾病的创新疾病修正疗法。AgomAb Therapeutics成立于2017年,计划以股票代码“AGMB”在纳斯达克上市。公司预计将于今年2月完成IPO定价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4539","BK4588","LENZ","BK4007","BK4139","AGMB","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agomab.com","stockEarnings":[{"period":"1week","weight":-0.008},{"period":"1month","weight":-0.0668},{"period":"3month","weight":-0.1053},{"period":"ytd","weight":-0.1053}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AgomAb Therapeutics NV最初于2017年4月13日根据比利时法律注册成立,是一家比利时私人有限责任公司。该公司是一家临床阶段的生物制药实体,致力于开发针对免疫学和炎症性疾病的创新疾病改善疗法,特别专注于存在重大未满足医疗需求的慢性纤维化疾病。其候选产品旨在针对既定途径,并使用经过验证的模式来增强疗效,同时最大限度地减少全身毒性,从而解决先前治疗的局限性。其使命是创造不仅能解决纤维化,还能恢复器官功能的疗法,让患者过上更充实、更健康的生活。","exchange":"NASDAQ","name":"AgomAb Therapeutics","nameEN":"AgomAb Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AgomAb Therapeutics(AGMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AgomAb Therapeutics,AGMB,AgomAb Therapeutics股票,AgomAb Therapeutics股票老虎,AgomAb Therapeutics股票老虎国际,AgomAb Therapeutics行情,AgomAb Therapeutics股票行情,AgomAb Therapeutics股价,AgomAb Therapeutics股市,AgomAb Therapeutics股票价格,AgomAb Therapeutics股票交易,AgomAb Therapeutics股票购买,AgomAb Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AgomAb Therapeutics(AGMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}